Julia A. Bridge, M.D.

Department Affiliations
Director, Tissue Banking Core Facility
Director, Sarcoma Rearrangement Testing for Molecular Diagnostics
Director, Nebraska Collaborative Laboratory 

Cytopathology, Pathology of Bone and Soft Tissue Tumors, Molecular Pathology
My research involves several aspects of genetics with special emphasis on cancer genetics of bone and soft tissue tumors. Over the years, we have identified a number of tumor specific chromosomal abnormalities, fusion transcripts, and/or genomic imbalances/mutations for both benign and malignant bone and soft tissue tumors as well as other solid tumors such as brain and kidney. These genetic abnormalities are important diagnostically and prognostically, as well as defining treatment strategies to include novel therapeutic targets. These data have also contributed significantly to our understanding of the histopathogenesis of many of these neoplasms..

Education and Training
B.S., University of Nebraska, Lincoln, NE, 1984
M.D., University of Nebraska Medical Center, Omaha, NE, 1984
Pathology Residency, University of Kansas Medical Center, Kansas City, KS, 1984-1988
Special Fellow in Cytogenetics, University of Nebraska Medical Center, University of Kansas Medical Center, 1988-1989
Molecular Biology Fellow, Southwest Biomedical Research Institute, Scottsdale, AZ, 1989-1990

Teaching Activities

National/International: Course Director/lecturer/invited speaker, molecular diagnostics, soft tissue/bone pathology, United States and Canadian Academy of Pathology (USCAP), Association for Molecular Pathology (AMP), Society for Pediatric Pathology (SPP), Connective Tissue Oncology Society (CTOS), American Academy of Orthopedic Surgeons (AAOS), Musculoskeletal Tumor Society (MSTS), College of American Pathologists (CAP), European Congress of Pathology (ECP), XXIII Pathology Meeting of A.C. Camargo Cancer Center Brazil

Nebraska Pathology Society
Faculty Advisor/Department Graduate committee
Residents/Fellows – cytopathology, cytogenetics, molecular pathology
Cytology Technologist Students - cytopathology

Medical Students – PBL,small groups facilitator, elective rotations

Digital/web-based -  Oakstone, CAP

National Activities

President, International Society of Bone and Soft Tissue Pathology (ISBSTP)
Secretarial Appointee to the Department of Veterans Affairs (VA) Genomic Medicine Program Advisory Committee
World Health Organization Classification (WHO) of Tumours of Soft Tissue and Bone Working Group and Editor
United States and Canadian Academy of Pathology (USCAP) Nominating Committee & Foundation Committee
Childrens Oncology Group (COG) Soft Tissue Sarcoma and Ewing Sarcoma Committees
College of American Pathologists (CAP)/American College of Medical Genetics (ACMG) Cytogenetics Resource Committee
College of American Pathologists (CAP)/ International Association for the Study of Lung Cancer (IASLC)/Association of Molecular Pathology (AMP) Lung Biomarker Advisory Panel
College of American Pathologists (CAP) Molecular Oncology Committee
College of American Pathologists (CAP)  Cancer Biomarker Reporting Committee, melanoma
Editorial Board, Cancer Genetics
Editorial Board, Cancer Cytopathology
Editorial Board, Modern Pathology
Alpha Omega Alpha Honor Medical Society

Notable Publications

Bridge JA, Nelson M. Genetics of Soft Tissue Pathology. In: M. Miettinen (ed), Modern Soft Tissue Pathology, Cambridge University Press, 2015.

Smith R, Kebriael MA, Gard AP, McComb RD, Bridge JA. Intracranial Malignant Triton Tumor in a Patient with Neurofibromatosis Type 1: Case Report and Review of the Literature. Brain Tumor Pathol, 31(2):149-154, 2014.

Pauli C, Fuchs B, Pfirrmann C, Bridge JA, Hofer S, Bode B.  Response of an aggressive periosteal aneurysmal bone cyst (ABC) of the radius to denosumab therapy.  World Journal of Surgical Oncology, 12(1):17, 2014.

Rudzinski ER, Anderson JR, Lyden ER, Bridge JA, Barr FG, Gastier-Foster JM, Bachmeyer K, Skapek SX, Wawkins DS, Teot LA, Parham DM.  Myogenin, AP2B, NOS-1 and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma.  Am J Surg Pathol. 38(5):654-9, 2014

Bridge JA. The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors.  Modern Pathology; 27:Suppl 1:S80-97, 2014

Linos K, Bridge JA, Edgar MA.  MUC 4 negative FUS-CREB3L2 rearranged Low Grade Fibromyxoid Sarcoma.  Histopathology, 2014 Nov;65(5):722-4.

Boyle TA, Bridge JA, Sabatini LM, Nowak JA, Vasalos P, Jennings LJ, Halling KC, College of American Pathologists Molecular Oncology Committee.  Summary of microsatellite instability test results from laboratories participating in proficiency surveys: proficiency surveys results from 2005 to 2012.  Arch Pathol Lab Med, 138(3):363-370, 2014

Smith NE, Deyrup AT, Marino-Enriquez A, Fletcher JA, Bridge JA, Illei PB, Netto GJ, Argani P.  VCL-ALK Renal Cell Carcinoma in Children with Sickle-Cell Trait: The Eighty Sickle-cell Nephropathy? Am J. Surg Pathol Jun;38(6):858-63, 2014

Kohsaka S, Shukla N, Ameur N, Lim D, Marchetti A, Viale A, Pirun M, Socci N, Xin L, Scoit R, Bridge JA, Meyers P, Wexler L, Dogan S, Fletcher J, Ladanyi M.  A recurrent neomorphic mutation of  MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma with frequent mutations activating AKT signaling.  Nat Genet. 2014 Jun;46(6):595-600

Monument MJ, Johnson KM, McLvaine E, Abelgglen L, Watkins WS, Jorde LB, Womer RB, Beeler N, Monovich L, Lawlor ER, Bridge JA, Schiffman JD, Krailo MD, Randall RL, Lessnisk SL.  Clinical and Biochemical function of polymorphic NROB1 GGAA-Microsatellites in Ewing Sarcoma: a report from the Children’s Oncology Group.  PLoS One 2014 Aug 5:9(8) e104378

Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone, 4th ed., IARC Press, Lyon, France. 2013

Bridge JA, Liu X, Sumegi J, Nelson M, Reyes C, Bruch LA, Rosenblum M, Puccioni, Bowdino BS, McComb RD. Identification of a Novel, Recurrent SLC44A1-PRKCA Fusion in Papillary Glioneuronal Tumor. Brain Pathol. 23(2):121-8, 2013.

Nestheide S, Bridge JA, Frayer R, Barnes M, Sumegi J. Pharmacologic Inhibition of Epigenetic Modification Reveals Targets of Aberrant Promoter Methylation in Ewing Sarcoma.  Pediatr Blood Cancer, 60(9):1437-1446, 2013.

Viray H, Li K, Long T, Vasalos P, Bridge JA, Jennings L, Halling K, Meera Hameed M, Rimm DL. A Prospective, Multi-Institutional Diagnostic Trial to Determine Pathologist Accuracy in Estimation of Percentage of Malignant Cells. Arch Pathol Lab Med, 137(11):1545-9, 2013.

Skapek SX, Anderson J, Barr FG, Bridge JA, Gastier-Foster J, Parham D, Rudzinski E, Triche T, Hawkins DS. PAX-FOXO1 Fusion Status Drives Unfavorable Outcome for Children With Rhabdomyosarcoma: A Children’s Oncology Group Report. Pediatr Blood Cancer, 60(9):1411-1417, 2013.

Rudzinski ER, Teot LA, Anderson JR, Moore J, CRA, HT(ASCP), Bridge JA, Barr FG, Gastier-Foster JM, Skapek SX, Hawkins DS, Parham DM. Dense Pattern of Embryonal Rhabdomyosarcoma, a Lesion Easily Confused with Alveolar Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Am J Clin Pathol. 140(1):82-90, 2013.

Demicco EG, Wang WL, MAdewell JE, Huang D, Bui MM, Bridge JA, Meis JM.  Osseous myxochondroid sarcoma: a detailed study of 5 cases of extraskeletal myxoid chondrosarcoma of the bone.  Am J Surg Pathol. 37(5): 752-762, 2013

Donnelly AD, Mukherjee MS, Lyden ER, Bridge JA, Lele SM, Wright N, McGaughey MF, Culberson AM, Horn AJ, Wedel WR, Radio SJ.  Optimal z-axis scanning parameters for gynecological cytology specimens.  J Pathol Inform;4:38, 2013.

For a detailed list of publications, click here.